📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $ImmunityBio(IBRX.US) ImmunityBio Reports Favorable Bladder Cancer Data at 𝐀𝐔𝐀 𝟐𝟎𝟐𝟔
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ 𝐀𝐍𝐊𝐓𝐈𝐕𝐀® + BCG showed stronger complete response outcomes versus competitors.➤ NAI+BCG patients were 𝟐× more likely to achieve complete response versus nadofaragene.➤ Median complete response duration reached 𝟐𝟐.𝟏 months versus 𝟗.𝟕 months.➤ NAI+BCG reduced 𝐜𝐲𝐬𝐭𝐞𝐜𝐭𝐨𝐦𝐲 risk by 𝟔𝟎% versus nadofaragene.➤ Compared with TAR-200, NAI+BCG showed numerically higher 𝟏𝟐-𝐦𝐨𝐧𝐭𝐡 CR rates.➤ NAI+BCG demonstrated significantly fewer 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 adverse events than TAR-200.➤ Data presented at 𝐀𝐔𝐀 𝟐𝟎𝟐𝟔 for BCG-unresponsive bladder cancer patients.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments